ANVS phase III Alzheimer’s trial enrolled; top-line due March
ANVS says its phase III Alzheimer’s trial is fully enrolled, with top-line data expected in March and an NDA filing to follow. It also plans a $15 million raise before Q4 to fund needs.
Pivotal phase III Alzheimer's trial is fully enrolled, with top-line data expected in March and NDA filing to follow.
Financial needs require a $15 million raise before Q4, with management and insiders participating.
Disease-modifying data and commercialization are targeted for 2028, and regulatory…